|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Synthesis, characterization and antibacterial studies of ferrocenyl and cymantrenyl hydrazone compounds显示文摘 | Vijaylakshmi Tirkey Sasmita Mishra Hirak R. Dash Surajit Das Bibhukalyan Prasad Nayak Shaikh M. Mobin Saurav Chatterjee | 2013 | Journal of Organometallic Chemistry2013，，： | 1 |
| 2 | Meta-Analysis of Left Ventricular Hypertrophy and Sustained Arrhythmias显示文摘 | Saurav Chatterjee Chirag Bavishi Partha Sardar Vikram Agarwal Parasuram Krishnamoorthy Tomasz Grodzicki Franz H. Messerli | 2014 | The American Journal of Cardiology2014，，7： | 1 |
| 3 | Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome显示文摘Cardiovascular death is the leading cause of mortality for patients with type 2 diabetes mellitus. The etiologyof cardiovascular disease in diabetes may be divided into hyperglycemia per se and factors operating through components of metabolic syndrome(Met S). Hyperglycemia causes direct injury to vascular endothelium and possibly on cardiac myocytes. Met S is a cluster of risk factors like obesity, hyperglycemia, hypertension and dyslipidemia. The incidence of this syndrome is rising globally. Glucagon-like peptide-1 receptor agonists(GLP-1RA) are a group of drugs, which address all components of this syndrome favorably. Experimental evidence suggests that they have favorable actions on myocardium as well. Several compounds belonging to GLP-1RA class are in market now and a large number awaiting their entry. Although, originally this class of drugs emerged as a treatment for type 2 diabetes mellitus, more recent data generated revealed beneficial effects on multiple metabolic parameters. We have studied literature published between 2000 and 2016 to look into effects of GLP-1RA on components of Met S. Results from recently concluded clinical trials suggest that some of the molecules in this class may have favorable effects on cardiovascular outcome. | Sanjay Chatterjee Samit Ghosal Saurav Chatterjee | 2016 | World Journal of Diabetes2016，7，18： | 1 |
| 4 | Thrombolysis for pulmonary embolism and risk of all- Cause mortality, major Bleeding, and intracranial hemorrhage A meta-analvsis 显示文摘 | Saurav Chatterjee MD Anasua Chakraborty MD Ido Weinberg MD | 2014 | JAMA2014，311，23： | 1 |
| 5 | Thrombolysis for pulmonary embolism and risk of all-Cause mortality, major Bleeding, and intracranial hemorrhage A meta-analysis 显示文摘 | Saurav Chatterjee MD Anasua Chakraborty MD Ido Weinberg MD | 2014 | JAMA2014，311，23： | 1 |
| 6 | Clopidogrel is safer than ticagrelor in regard to bleeds: A closer look at the PLATO trial显示文摘 | James J. DiNicolantonio Fabrizio D’Ascenzo Ales Tomek Saurav Chatterjee Asfandyar K. Niazi Giuseppe Biondi-Zoccai | 2013 | International Journal of Cardiology2013，，： | 1 |
| 7 | Clopidogrel is safer than ticagrelor in regard to bleeds: A closer look at the PLATO trial显示文摘 | James J. DiNicolantonio Fabrizio D’Ascenzo Ales Tomek Saurav Chatterjee Asfandyar K. Niazi Giuseppe Biondi-Zoccai | 2013 | International Journal of Cardiology2013，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员